title: In vitro sensitivity of Kaposi's sarcoma cells to various chemotherapeutic agents including acyclic nucleoside phosphonates.
abstract: The involvement of a viral agent in the pathogenesis of Kaposi's sarcoma (KS) points to antiviral agents as possible therapeutic and/or prophylactic options in the management of the disease. In the present study we investigated the antiproliferative effects of various chemotherapeutic agents, including acyclic nucleoside phosphonates, on the growth of KS-derived cells. Nested PCR amplification demonstrated that these cells do not contain human herpesvirus 8 (HHV-8) DNA sequences. The cytotoxicity of the chemotherapeutic compounds was less pronounced in KS cells than in human dermal microvascular endothelial cells, which are considered to be the normal counterpart of KS cells. Stimulation of KS cells with basic fibroblast growth factor (bFGF) and correction of the IC50 values by the doubling times revealed that the apparent chemotherapeutic resistance of KS cells could mainly be attributed to the long doubling times of these cells. bFGF-stimulated KS cells still exhibited no particular sensitivity to the acyclic nucleoside phosphonates whose activity extends to HHV-8, which is consistent with the absence of linear HHV-8 DNA synthesis in these cells. Our data suggest that neither anti-cancer agents nor antiviral agents such as the acyclic nucleoside phosphonates can discriminate efficiently between KS cells and normal endothelial cells.
authors.affiliation: Department of Dermatology, Erasme University Hospital, Brussels, Belgium.
authors.forename: T
authors.initials: T
authors.lastname: Simonart
authors.forename: G
authors.initials: G
authors.lastname: Andrei
authors.forename: D
authors.initials: D
authors.lastname: Parent
authors.forename: J P
authors.initials: JP
authors.lastname: Van Vooren
authors.forename: E
authors.initials: E
authors.lastname: De Clercq
authors.forename: R
authors.initials: R
authors.lastname: Snoeck
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology*; D004279:DNA, Viral / Q000032:analysis; D004354:Drug Screening Assays, Antitumor; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D019288:Herpesvirus 8, Human / Q000737:chemistry; D006801:Humans; D020128:Inhibitory Concentration 50; D009705:Nucleosides / Q000494:pharmacology*; D063065:Organophosphonates / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D012514:Sarcoma, Kaposi / Q000473:pathology* / Q000821:virology; D012878:Skin Neoplasms / Q000473:pathology* / Q000821:virology; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D004279:DNA, Viral; D009705:Nucleosides; D063065:Organophosphonates; D016222:Fibroblast Growth Factor 2